The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Checkpoint inhibitor immunotherapies targeting CTLA4 or PD1 pathways have shown significant success in treating various cancers.
• However, only a fraction of patients benefit clinically from these treatments, necessitating an understanding of response determinants.
• Identifying factors influencing response, resistance, and adverse effects is critical for optimizing cancer immunotherapy.

Purpose of the Study:

• To review recent findings on molecular and cellular determinants affecting immune checkpoint inhibitor efficacy.
• To explore the interplay of tumor genomics, host germline genetics, PDL1 expression, tumor microenvironment, and gut microbiome in immunotherapy response.
• To highlight the need for a comprehensive understanding of these variables for advancing precision immunotherapy.

Main Methods:

• Review of recent scientific literature and research findings.
• Analysis of factors influencing immune checkpoint inhibitor efficacy.
• Focus on molecular and cellular determinants of response, resistance, and adverse effects.

Main Results:

• Immune checkpoint inhibitor efficacy is influenced by a combination of factors.
• These include tumor genomics, host germline genetics, PDL1 levels, tumor microenvironment characteristics, and the gut microbiome.
• Recently identified molecular and cellular determinants play a role in treatment response.

Conclusions:

• A deeper understanding of how tumor genomics, host genetics, PDL1, tumor microenvironment, and gut microbiome interact is crucial.
• Optimizing the implementation of precision immunotherapy requires a holistic view of these cooperating variables.
• Further research into these determinants will enhance the effectiveness of cancer immunotherapies.